High @entity11833 expression predicts XXXX -based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.

@entity1 @entity11833 @entity167 @entity900 @entity982 @entity213
BACKGROUND: This study was to evaluate the effect of excision repair cross-complementation group 1( @entity11833 ) expression on response to @entity900 -based induction chemotherapy (IC) followed by concurrent chemoradiation (CCRT) in locally advanced unresectable @entity213 ( @entity213 ) @entity1 . METHODS: Fifty-seven @entity1 with locally advanced unresectable @entity213 who received @entity900 -based IC followed by CCRT from January 1, 2006 through January 1, 2008. Eligibility criteria included presence of biopsy-proven @entity213 without a prior history of chemotherapy or radiotherapy. Immunohistochemistry was used to assess @entity11833 expression in pretreatment biopsy specimens from @entity982 blocks. Clinical parameters, including smoking, @entity167 consumption and betel nuts chewing, were obtained from the medical records. RESULTS: The 12-month progression-free survival (PFS) and 2-year overall survival (OS) rates of fifty-seven @entity1 were 61.1% and 61.0%, respectively. Among these @entity1 , thirty-one @entity1 had low @entity11833 expression and forty-one @entity1 responded to IC followed by CCRT. Univariate analyses showed that @entity1 with low expression of @entity11833 had a significantly higher 12-month PFS rates (73.3% vs. 42.3%, p < 0.001) and 2-year OS (74.2 vs. 44.4%, p = 0.023) rates. Multivariate analysis showed that for @entity1 who did not chew betel nuts and had low expression of @entity11833 were independent predictors for prolonged survival. CONCLUSIONS: Our study suggest that a high expression of @entity11833 predict a poor response and survival to @entity900 -based IC followed by CCRT in @entity1 with locally advanced unresectable @entity213 in betel nut chewing area.
